We confirmed that combined lenvatinib and anti-PD-L1 pembrolizumab treatment significantly reduced the MCGs risk score in HCC liver cancer (GSE148355) (Supplementary Figure S7F). This evidence concerns the gene CD274 and hepatocellular carcinoma.